【摘要】 目的观察紫杉醇亚微球对小鼠乳腺癌的治疗效果。方法以可生物降解材料聚己内酯(poly-caprolacton,PCL)为原料,采用溶剂替代法制备载紫杉醇亚微球。并对亚微球的粒径、形态、紫杉醇含量、体外释放等进行了测定。将TA2系实验小鼠随机分为空白对照组、紫素阳性对照组、紫杉醇亚微球低剂量组、紫杉醇亚微球中剂量组及紫杉醇亚微球高剂量组。实验时分别将生理盐水、紫素、紫杉醇亚微球注射到小鼠乳腺癌部位,通过测量治疗前后肿瘤大小,观察紫杉醇亚微球治疗实验小鼠乳腺癌的效果。结果制备的紫杉醇亚微球的平均粒径约为566nm,包埋率为93.25%,亚微球中紫杉醇含量约19.0536%。可在体外维持恒定释放约4周。药物注射2周观察抑瘤率:紫杉醇亚微球中剂量组为70.21%,紫杉醇亚微球高剂量组为84.16%,与紫素阳性对照组(48.96%)比较差异有显著统计学意义(P<0.001)。紫杉醇亚微球低剂量组为45.47%,与紫素阳性对照组相比,两者差异亦有显著统计学意义(P<0.001)。结论紫杉醇亚微球(中剂量组和高剂量组)对小鼠乳腺癌的抑瘤率高于紫素。更多还原

【Abstract】 Objective To study the therapeutic efficacy of paclitaxel-PCL nanoparticles in mouse breast cancer. Methods A biodegradable poly-caprolacton(PCL) was adopted as drug delivery material. Paclitaxel drug delivery nanoparticles(NP) were prepared by a multi-emulsification technique. The nanoparticles were characterized for size,drug loading capacity,and in vitro release. The experimental mice were randomly divided into vacant control group,paclitaxel positive control group,Paclitaxel-NP low-dose group,Paclitaxel-NP meta-dose group and Paclitaxel-NP high dose group. Paclitaxel or Paclitaxel-NP was injected into mouse breast cancer,then the tumor size was measured. Results The average size of Paclitaxel-NP was around 300 nm. The encapsulation efficiency of Paclitaxel was above 96 %. Loading amount of Paclitaxel in the nanoparticles was about 4 %. In vitro,nanoparticles maintained sustaining release of Paclitaxel for 2 weeks. After 2 week,the inhibition ratio of tumor growth in Paclitaxel-NP meta-dose group was 70.21 %,in Paclitaxel-NP high dose group was 84.16 %,in Paclitaxel positive control group was 48.96 %. The differences of both groups compared with control were significant(P < 0.001);in Paclitaxel-NP low-dose group was 45.4 %,showing was significant difference compared with control(P < 0.001). Conclusion The inhibition ratio of tumor growth in Paclitaxel-NP (meta-dose group and high dose group) is higher than that in paclitaxel group.更多还原